Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Inclusion Criteria:

• Ph+ CML on dasatinib therapy
• Loss of cytogenetic or molecular response while on dasatinib therapy
• On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment

Exclusion Criteria:

• Blast crisis CML
• Autoimmune disease
• Uncontrolled or significant cardiovascular disease